The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Inclusion criteria

• 18 years old≤ Aged ≤80 years old.
• Diagnosis of malignancy.
• Malignant tumors initially treated with immune checkpoint inhibitors (antibodies targeting PD-1, PD-L1, CTLA-4, or new immune checkpoint inhibitors) in combination with or without chemotherapy.
• Diagnosis of grade 3 or 4 CIP: CIP severity at CTCAE grade 3 or 4.
• Patients who and whose family members understand the study protocol, are willing to participate in the study and could provide written informed consent.

Exclusion criteria

• Predicted life expectancy<12 weeks.
• Any evidence of active or uncontrolled viral infection, including hepatitis B, hepatitis C and human immunodeficiency virus (HIV), or any clinical signs of bacterial, other viral, parasitic or fungal infection requiring treatment.
• malignancy progression.
• Patients with other serious complications that may affect safety or adherence judged by the investigator.
• Any significant clinical and laboratory abnormalities judged by investigator that affect the safety evaluation.
• Patients can't fully understand the study protocol, arrangement and other study-related elements.
• Patients with evidence of severe liver or kidney dysfunction judged by investigator unsuitable for enrolment.
• Women who are pregnant, breast feeding or unable to use effective contraception during the study period and for 3 months after the completion.
• Patients who cannot comply with study treatment and follow-up according to the trial protocol.